A Clinical Study to Evaluate the Long-Term Safety Sodium Oligomannate Capsules (GV-971)

StatusActive, Not Recruiting
PhasePhase 4
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

  1. Re-verified, no change to tracked fieldsv6
  2. Primary completion date: Apr 2024 to Jan 2025v5
  3. Trial status: Recruiting to Active, Not Recruiting
    • Site details revised at 63 of 63 sites
    v4
  4. Primary completion date: Dec 2022 to Apr 2024
    • Study sites: 65 to 63
    • Study completion date: Jun 2024 to Apr 2025
    v3
  5. Lead sponsor: Shanghai Greenvalley Pharmaceutical Co., Ltd. to Green Valley (Shanghai) Pharmaceuticals Co., Ltd.
    • Study sites: 61 to 65
    v2
  6. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
A clinical study to evaluate the long-term safety of Sodium Oligomannate Capsules (GV-971)
Trial Details
NCT Number NCT05058040
Lead Sponsor Green Valley (Shanghai) Pharmaceuticals Co., Ltd.
Conditions
(from sponsor)		 Alzheimer Disease
Related terms Alzheimer Disease
Enrollment 2,500 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov